Backers included Cresco Capital Partners II, LLC, Flatiron Venture Partners and Delta Emerald Ventures.
The company intends to use the funds to accelerate the development of proprietary cells for the production of pure, natural, pharmaceutical-grade cannabinoids via fermentation.
Founded in 2017 by Ben Chiarelli, chief executive officer, Cellibre employs an organism-agnostic approach to turn cells into specialized, sustainable factories for the manufacture of globally significant products at scale.
The company’s initial strategic focus will be deploying expertise to enable the production of pharmaceutical-grade cannabinoids.
FinSMEs
05/06/2019